Skip to main content
Clinical Trials/NL-OMON32507
NL-OMON32507
Not yet recruiting
Not Applicable

The difference in fractional cholesterol absorption between subjects with high versus low plasma campesterol levels - DAHLIA-2

Academisch Medisch Centrum0 sites13 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
mild hypercholesterolaemia
Sponsor
Academisch Medisch Centrum
Enrollment
13
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Healthy male and female subjects, aged 18\-65 years old, with an LDL\-cholesterol concentration between 3\.0 and 5\.0 mmol/l, who participated in the Dahlia\-1 study and belong to the 6 subjects with the highest or to the 6 subjects with the lowest plasma campesterol levels respectively. One subject with the subsequently highest campesterol levels will be asked to undergo a cholesterolabsorption measurement as well, in order for us to test the quantification of cholesterol isotopes by our laboratory.

Exclusion Criteria

  • Excluded are persons with a genetic hyperlipoproteinemia like familial hypercholesterolemia, LPL\-deficiency, familial dysbeta lipoproteinemia and familial hypertriglyceridemia. Also people with diabetes mellitus, severe hypertriglyceridemia, uncontrolled hypertension or history of arterial disease including unstable angina, myocardial infarction, recent transient ischaemic attacks or a cerebro\-vascular accident, will be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Therapeutic effects of cholesterol absorption inhibitor on renal function in patients with chronic kidney diseaseChronic kidney disease Hypercholesterolemia
JPRN-UMIN000002528Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine50
Completed
Phase 4
Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSoundpatients aged 30-85 years who were undergoing percutaneous coronary intervention (PCI, elective or emergency) with &gt=1 significant stenosis &gt=75% and &gt=1 untouched nonculprit lesion of &lt=50% stenosis that could be imaged by intravascular ultrasound, and either LDL-C &gt=100 mg/dl.
JPRN-UMIN000002959Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University300
Completed
Not Applicable
The study about the effects of cholesterol absorption inhibition on coronary artery plaque in patients treated with PCIcoronary artery diseases
JPRN-UMIN000026581Kurume University Medical Center50
Not yet recruiting
Not Applicable
Validation of cholesterol absorption as measured by the dual isotope methodmild hypercholesterolemiaslightly elevated cholesterol10013317
NL-OMON34258Academisch Medisch Centrum7
Completed
Not Applicable
Cholesterol Absorption and Cholesterol synthesis in High-risk patiEnts (CACHE study)1. Cardiovascular disease (coronary arterial disease, cerebrovascular disease, peripheral arterial disease) 2. Conditions at high risk of cardiovascular disease (diabetes mellitus, chronic kidney disease including stage 5D) 3. Those who do not have the above diseases
JPRN-UMIN000030635Osaka City University3,000